» Articles » PMID: 20154697

An Oncogene-tumor Suppressor Cascade Drives Metastatic Prostate Cancer by Coordinately Activating Ras and Nuclear Factor-kappaB

Abstract

Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappaB (NF-kappaB). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappaB and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.

Citing Articles

Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.

Goleij P, Heidari M, Tabari M, Hadipour M, Rezaee A, Javan A Funct Integr Genomics. 2025; 25(1):53.

PMID: 40048009 DOI: 10.1007/s10142-025-01563-8.


Impact of loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Slootbeek P, Luna-Velez M, Prive B, van der Doelen M, Kloots I, Pamidimarri Naga S Theranostics. 2024; 14(12):4555-4569.

PMID: 39239510 PMC: 11373632. DOI: 10.7150/thno.96322.


Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer.

Yu Y, Li L, Yang Q, Xue J, Wang B, Xie M Microorganisms. 2024; 12(8).

PMID: 39203495 PMC: 11356635. DOI: 10.3390/microorganisms12081653.


Exploring the Genetic Landscape of Vitiligo in the Pura Raza Español Horse: A Genomic Perspective.

Laseca N, Molina A, Perdomo-Gonzalez D, Ziadi C, Azor P, Valera M Animals (Basel). 2024; 14(16).

PMID: 39199954 PMC: 11350783. DOI: 10.3390/ani14162420.


An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications.

De Florian Fania R, Bellazzo A, Collavin L Cell Death Differ. 2024; 31(7):844-854.

PMID: 38902547 PMC: 11239834. DOI: 10.1038/s41418-024-01332-3.


References
1.
Johannessen C, Reczek E, James M, Brems H, Legius E, Cichowski K . The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005; 102(24):8573-8. PMC: 1142482. DOI: 10.1073/pnas.0503224102. View

2.
Sorensen H, Mellemkjaer L, Olsen J, Baron J . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-50. DOI: 10.1056/NEJM200012213432504. View

3.
Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

4.
Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, Montgomery K . Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004; 101(3):811-6. PMC: 321763. DOI: 10.1073/pnas.0304146101. View

5.
Kondo Y, Shen L, Cheng A, Ahmed S, Boumber Y, Charo C . Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40(6):741-50. DOI: 10.1038/ng.159. View